FUTURE2 analysis of 78 TJC and 76 SJC scores in PsA pts treated with SEC demonstrated improvements in synovitis at Week 24 sustained over 5 years, irrespective of TNFi history & concomitant MTX use. #ABS0875 #ACR20#ACRbest @RheumNow https://t.co/U8B50PTWET https://t.co/fUK1JO10ox
Links:
Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tende…
http://ow.ly/U0uH50C9c68
07-11-2020